Šumarac, Zorica

Link to this page

Authority KeyName Variants
8b045123-95a6-4542-875e-c9d87a735bca
  • Šumarac, Zorica (8)
Projects

Author's Bibliography

Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer

Jovanović, Dragana; Roksandić-Milenković, Marina; Kotur-Stevuljević, Jelena; Ceriman, Vesna; Vukanić, Ivana; Samardžić, Natalija; Popević, Spasoje; Ilić, Branislav; Gajić, Milija; Simon, Marioara; Simon, Ioan; Spasojević-Kalimanovska, Vesna; Belić, Milica; Mirkov, Damjan; Šumarac, Zorica; Milenković, Vladislav

(Društvo medicinskih biohemičara Srbije, Beograd i Versita, 2019)

TY  - JOUR
AU  - Jovanović, Dragana
AU  - Roksandić-Milenković, Marina
AU  - Kotur-Stevuljević, Jelena
AU  - Ceriman, Vesna
AU  - Vukanić, Ivana
AU  - Samardžić, Natalija
AU  - Popević, Spasoje
AU  - Ilić, Branislav
AU  - Gajić, Milija
AU  - Simon, Marioara
AU  - Simon, Ioan
AU  - Spasojević-Kalimanovska, Vesna
AU  - Belić, Milica
AU  - Mirkov, Damjan
AU  - Šumarac, Zorica
AU  - Milenković, Vladislav
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
AB  - Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
VL  - 38
IS  - 3
SP  - 332
EP  - 341
DO  - 10.2478/jomb-2018-0036
ER  - 
@article{
author = "Jovanović, Dragana and Roksandić-Milenković, Marina and Kotur-Stevuljević, Jelena and Ceriman, Vesna and Vukanić, Ivana and Samardžić, Natalija and Popević, Spasoje and Ilić, Branislav and Gajić, Milija and Simon, Marioara and Simon, Ioan and Spasojević-Kalimanovska, Vesna and Belić, Milica and Mirkov, Damjan and Šumarac, Zorica and Milenković, Vladislav",
year = "2019",
abstract = "Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer",
volume = "38",
number = "3",
pages = "332-341",
doi = "10.2478/jomb-2018-0036"
}
Jovanović, D., Roksandić-Milenković, M., Kotur-Stevuljević, J., Ceriman, V., Vukanić, I., Samardžić, N., Popević, S., Ilić, B., Gajić, M., Simon, M., Simon, I., Spasojević-Kalimanovska, V., Belić, M., Mirkov, D., Šumarac, Z.,& Milenković, V.. (2019). Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 332-341.
https://doi.org/10.2478/jomb-2018-0036
Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ceriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry. 2019;38(3):332-341.
doi:10.2478/jomb-2018-0036 .
Jovanović, Dragana, Roksandić-Milenković, Marina, Kotur-Stevuljević, Jelena, Ceriman, Vesna, Vukanić, Ivana, Samardžić, Natalija, Popević, Spasoje, Ilić, Branislav, Gajić, Milija, Simon, Marioara, Simon, Ioan, Spasojević-Kalimanovska, Vesna, Belić, Milica, Mirkov, Damjan, Šumarac, Zorica, Milenković, Vladislav, "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer" in Journal of Medical Biochemistry, 38, no. 3 (2019):332-341,
https://doi.org/10.2478/jomb-2018-0036 . .
21
14
22

Uncertainty of Measurement in Laboratory Medicine

Milinković, Neda; Ignjatović, Svetlana; Šumarac, Zorica; Majkić-Singh, Nada

(Društvo medicinskih biohemičara Srbije, Beograd i Versita, 2018)

TY  - JOUR
AU  - Milinković, Neda
AU  - Ignjatović, Svetlana
AU  - Šumarac, Zorica
AU  - Majkić-Singh, Nada
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3210
AB  - An adequate assessment of the measurement uncertainty in a laboratory medicine is one of the most important factors for a reliable interpretation of the results. A large number of standards and guidelines indicate the need for a proper assessment of the uncertainty of measurement results in routine laboratory practice. The available documents gene rally recommend participation in the proficiency schemes/external quality control, as well as the internal quality control, in order to primarily verify the quality performance of the method. Although all documents meet the requirements of the International Standard, ISO 15189, the standard itself does not clearly define the method by which the measurement results need to be assessed and there is no harmonization in practice regarding to this. Also, the uncertainty of measurement results is the data relating to the measured result itself, but all factors that influence the interpretation of the measured value, which is ultimately used for diagnosis and monitoring of the patient's treatment, should be taken into account. So in laboratory medicine, an appropriate assessment of the uncertainty of the measurement results should have the ultimate goal of reducing diagnostic uncertainty. However, good professional laboratory practice and understanding analytical aspects of the test for each individual laboratory is necessary to adequately define the uncertainty of measurement results for specific laboratory tests, which helps to implement good clinical practice. Also, setting diagnoses in medicine is a decision with a certain degree of uncertainty, rather than statistically and mathematically calculated conclusion.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Uncertainty of Measurement in Laboratory Medicine
VL  - 37
IS  - 3
SP  - 279
EP  - 288
DO  - 10.2478/jomb-2018-0002
ER  - 
@article{
author = "Milinković, Neda and Ignjatović, Svetlana and Šumarac, Zorica and Majkić-Singh, Nada",
year = "2018",
abstract = "An adequate assessment of the measurement uncertainty in a laboratory medicine is one of the most important factors for a reliable interpretation of the results. A large number of standards and guidelines indicate the need for a proper assessment of the uncertainty of measurement results in routine laboratory practice. The available documents gene rally recommend participation in the proficiency schemes/external quality control, as well as the internal quality control, in order to primarily verify the quality performance of the method. Although all documents meet the requirements of the International Standard, ISO 15189, the standard itself does not clearly define the method by which the measurement results need to be assessed and there is no harmonization in practice regarding to this. Also, the uncertainty of measurement results is the data relating to the measured result itself, but all factors that influence the interpretation of the measured value, which is ultimately used for diagnosis and monitoring of the patient's treatment, should be taken into account. So in laboratory medicine, an appropriate assessment of the uncertainty of the measurement results should have the ultimate goal of reducing diagnostic uncertainty. However, good professional laboratory practice and understanding analytical aspects of the test for each individual laboratory is necessary to adequately define the uncertainty of measurement results for specific laboratory tests, which helps to implement good clinical practice. Also, setting diagnoses in medicine is a decision with a certain degree of uncertainty, rather than statistically and mathematically calculated conclusion.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Uncertainty of Measurement in Laboratory Medicine",
volume = "37",
number = "3",
pages = "279-288",
doi = "10.2478/jomb-2018-0002"
}
Milinković, N., Ignjatović, S., Šumarac, Z.,& Majkić-Singh, N.. (2018). Uncertainty of Measurement in Laboratory Medicine. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 37(3), 279-288.
https://doi.org/10.2478/jomb-2018-0002
Milinković N, Ignjatović S, Šumarac Z, Majkić-Singh N. Uncertainty of Measurement in Laboratory Medicine. in Journal of Medical Biochemistry. 2018;37(3):279-288.
doi:10.2478/jomb-2018-0002 .
Milinković, Neda, Ignjatović, Svetlana, Šumarac, Zorica, Majkić-Singh, Nada, "Uncertainty of Measurement in Laboratory Medicine" in Journal of Medical Biochemistry, 37, no. 3 (2018):279-288,
https://doi.org/10.2478/jomb-2018-0002 . .
37
24
32

Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study

Popević, Spasoje; Šumarac, Zorica; Jovanović, Dragana; Babić, Dragan; Stjepanović, Mihailo; Jovičić, Snežana; Sobić-Saranović, Dragana; Filipović, Snežana; Gvozdenović, Branko; Omcikus, Maja; Milovanović, Andela; Videnović-Ivanov, Jelica; Radović, Ana; Zugić, Vladimir; Vučinić-Mihailović, Violeta

(Društvo medicinskih biohemičara Srbije, Beograd i Versita, 2016)

TY  - JOUR
AU  - Popević, Spasoje
AU  - Šumarac, Zorica
AU  - Jovanović, Dragana
AU  - Babić, Dragan
AU  - Stjepanović, Mihailo
AU  - Jovičić, Snežana
AU  - Sobić-Saranović, Dragana
AU  - Filipović, Snežana
AU  - Gvozdenović, Branko
AU  - Omcikus, Maja
AU  - Milovanović, Andela
AU  - Videnović-Ivanov, Jelica
AU  - Radović, Ana
AU  - Zugić, Vladimir
AU  - Vučinić-Mihailović, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2749
AB  - Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study
VL  - 35
IS  - 4
SP  - 390
EP  - 400
DO  - 10.1515/jomb-2016-0017
ER  - 
@article{
author = "Popević, Spasoje and Šumarac, Zorica and Jovanović, Dragana and Babić, Dragan and Stjepanović, Mihailo and Jovičić, Snežana and Sobić-Saranović, Dragana and Filipović, Snežana and Gvozdenović, Branko and Omcikus, Maja and Milovanović, Andela and Videnović-Ivanov, Jelica and Radović, Ana and Zugić, Vladimir and Vučinić-Mihailović, Violeta",
year = "2016",
abstract = "Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study",
volume = "35",
number = "4",
pages = "390-400",
doi = "10.1515/jomb-2016-0017"
}
Popević, S., Šumarac, Z., Jovanović, D., Babić, D., Stjepanović, M., Jovičić, S., Sobić-Saranović, D., Filipović, S., Gvozdenović, B., Omcikus, M., Milovanović, A., Videnović-Ivanov, J., Radović, A., Zugić, V.,& Vučinić-Mihailović, V.. (2016). Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 35(4), 390-400.
https://doi.org/10.1515/jomb-2016-0017
Popević S, Šumarac Z, Jovanović D, Babić D, Stjepanović M, Jovičić S, Sobić-Saranović D, Filipović S, Gvozdenović B, Omcikus M, Milovanović A, Videnović-Ivanov J, Radović A, Zugić V, Vučinić-Mihailović V. Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry. 2016;35(4):390-400.
doi:10.1515/jomb-2016-0017 .
Popević, Spasoje, Šumarac, Zorica, Jovanović, Dragana, Babić, Dragan, Stjepanović, Mihailo, Jovičić, Snežana, Sobić-Saranović, Dragana, Filipović, Snežana, Gvozdenović, Branko, Omcikus, Maja, Milovanović, Andela, Videnović-Ivanov, Jelica, Radović, Ana, Zugić, Vladimir, Vučinić-Mihailović, Violeta, "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study" in Journal of Medical Biochemistry, 35, no. 4 (2016):390-400,
https://doi.org/10.1515/jomb-2016-0017 . .
40
23
40

Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy

Mitrović, Mirjana; Šumarac, Zorica; Antić, Darko; Bogdanović, Andrija; Elezović, Ivo; Vukosavljević, Dragana; Ignjatović, Svetlana; Majkić-Singh, Nada; Suvajdzić, Nada

(Academic Press Inc Elsevier Science, San Diego, 2012)

TY  - JOUR
AU  - Mitrović, Mirjana
AU  - Šumarac, Zorica
AU  - Antić, Darko
AU  - Bogdanović, Andrija
AU  - Elezović, Ivo
AU  - Vukosavljević, Dragana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Suvajdzić, Nada
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1754
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Blood Cells Molecules and Diseases
T1  - Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy
VL  - 49
IS  - 1
SP  - 58
EP  - 59
DO  - 10.1016/j.bcmd.2012.03.003
ER  - 
@article{
author = "Mitrović, Mirjana and Šumarac, Zorica and Antić, Darko and Bogdanović, Andrija and Elezović, Ivo and Vukosavljević, Dragana and Ignjatović, Svetlana and Majkić-Singh, Nada and Suvajdzić, Nada",
year = "2012",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Blood Cells Molecules and Diseases",
title = "Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy",
volume = "49",
number = "1",
pages = "58-59",
doi = "10.1016/j.bcmd.2012.03.003"
}
Mitrović, M., Šumarac, Z., Antić, D., Bogdanović, A., Elezović, I., Vukosavljević, D., Ignjatović, S., Majkić-Singh, N.,& Suvajdzić, N.. (2012). Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy. in Blood Cells Molecules and Diseases
Academic Press Inc Elsevier Science, San Diego., 49(1), 58-59.
https://doi.org/10.1016/j.bcmd.2012.03.003
Mitrović M, Šumarac Z, Antić D, Bogdanović A, Elezović I, Vukosavljević D, Ignjatović S, Majkić-Singh N, Suvajdzić N. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy. in Blood Cells Molecules and Diseases. 2012;49(1):58-59.
doi:10.1016/j.bcmd.2012.03.003 .
Mitrović, Mirjana, Šumarac, Zorica, Antić, Darko, Bogdanović, Andrija, Elezović, Ivo, Vukosavljević, Dragana, Ignjatović, Svetlana, Majkić-Singh, Nada, Suvajdzić, Nada, "Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy" in Blood Cells Molecules and Diseases, 49, no. 1 (2012):58-59,
https://doi.org/10.1016/j.bcmd.2012.03.003 . .
7
5
7

Biomarkers in Serbian patients with Gaucher disease

Šumarac, Zorica; Suvajdzić, Nada; Ignjatović, Svetlana; Majkić-Singh, Nada; Janić, Dragana; Petakov, Milan; Đorđević, Maja; Mitrović, Mirjana; Dajak, Marijana; Golubović, Milka; Rodić, Predrag

(Pergamon-Elsevier Science Ltd, Oxford, 2011)

TY  - JOUR
AU  - Šumarac, Zorica
AU  - Suvajdzić, Nada
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Janić, Dragana
AU  - Petakov, Milan
AU  - Đorđević, Maja
AU  - Mitrović, Mirjana
AU  - Dajak, Marijana
AU  - Golubović, Milka
AU  - Rodić, Predrag
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1553
AB  - Objectives: The aim of the study was to evaluate the efficiency of the biomarkers chitotriosidase (Chito), total acid phosphatase (TACP), angiotensin converting enzyme (ACE) and ferritin in the diagnosis of Gaucher disease (GD) and to assess the utility of biomarkers for monitoring the effects of enzyme replacement therapy (ERT). Design and methods: Forty treatment-naive Gaucher patients were studied. 27/40 GP were put on ERT and monitored every 6 months. Results: The baseline median values of Chito, TACP, ACE and ferritin were highly elevated in GP: 10216 nmol/mL/h, 26.1 U/L, 253 U/L, 515 mu g/L, and 555 mu g/L, respectively. The only significant difference between mild and moderate GP subgroups is observed for Chito activity (p=0.0116). During ERT, Chito showed the steepest decrease in regard to TACP and ACE, mainly within the first year (71.4%). Conclusions: Among these biomarkers, Chito proved to be the most useful biomarker for diagnosing GD and monitoring the ERT.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Biomarkers in Serbian patients with Gaucher disease
VL  - 44
IS  - 12
SP  - 950
EP  - 954
DO  - 10.1016/j.clinbiochem.2011.05.016
ER  - 
@article{
author = "Šumarac, Zorica and Suvajdzić, Nada and Ignjatović, Svetlana and Majkić-Singh, Nada and Janić, Dragana and Petakov, Milan and Đorđević, Maja and Mitrović, Mirjana and Dajak, Marijana and Golubović, Milka and Rodić, Predrag",
year = "2011",
abstract = "Objectives: The aim of the study was to evaluate the efficiency of the biomarkers chitotriosidase (Chito), total acid phosphatase (TACP), angiotensin converting enzyme (ACE) and ferritin in the diagnosis of Gaucher disease (GD) and to assess the utility of biomarkers for monitoring the effects of enzyme replacement therapy (ERT). Design and methods: Forty treatment-naive Gaucher patients were studied. 27/40 GP were put on ERT and monitored every 6 months. Results: The baseline median values of Chito, TACP, ACE and ferritin were highly elevated in GP: 10216 nmol/mL/h, 26.1 U/L, 253 U/L, 515 mu g/L, and 555 mu g/L, respectively. The only significant difference between mild and moderate GP subgroups is observed for Chito activity (p=0.0116). During ERT, Chito showed the steepest decrease in regard to TACP and ACE, mainly within the first year (71.4%). Conclusions: Among these biomarkers, Chito proved to be the most useful biomarker for diagnosing GD and monitoring the ERT.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Biomarkers in Serbian patients with Gaucher disease",
volume = "44",
number = "12",
pages = "950-954",
doi = "10.1016/j.clinbiochem.2011.05.016"
}
Šumarac, Z., Suvajdzić, N., Ignjatović, S., Majkić-Singh, N., Janić, D., Petakov, M., Đorđević, M., Mitrović, M., Dajak, M., Golubović, M.,& Rodić, P.. (2011). Biomarkers in Serbian patients with Gaucher disease. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 44(12), 950-954.
https://doi.org/10.1016/j.clinbiochem.2011.05.016
Šumarac Z, Suvajdzić N, Ignjatović S, Majkić-Singh N, Janić D, Petakov M, Đorđević M, Mitrović M, Dajak M, Golubović M, Rodić P. Biomarkers in Serbian patients with Gaucher disease. in Clinical Biochemistry. 2011;44(12):950-954.
doi:10.1016/j.clinbiochem.2011.05.016 .
Šumarac, Zorica, Suvajdzić, Nada, Ignjatović, Svetlana, Majkić-Singh, Nada, Janić, Dragana, Petakov, Milan, Đorđević, Maja, Mitrović, Mirjana, Dajak, Marijana, Golubović, Milka, Rodić, Predrag, "Biomarkers in Serbian patients with Gaucher disease" in Clinical Biochemistry, 44, no. 12 (2011):950-954,
https://doi.org/10.1016/j.clinbiochem.2011.05.016 . .
12
9
11

Could depression be a new branch of MIA syndrome?

Simić-Ogrizović, Sanja; Jovanović, D.; Dopsaj, Violeta; Radović, M.; Šumarac, Zorica; Bogavac-Stanojević, Nataša; Stošović, Milan; Stanojević, M.; Nesić, V.

(Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen, 2009)

TY  - JOUR
AU  - Simić-Ogrizović, Sanja
AU  - Jovanović, D.
AU  - Dopsaj, Violeta
AU  - Radović, M.
AU  - Šumarac, Zorica
AU  - Bogavac-Stanojević, Nataša
AU  - Stošović, Milan
AU  - Stanojević, M.
AU  - Nesić, V.
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1251
AB  - The aims of the present study were to determine the prevalence of depression in our dialysis patients, to detect the most powerful variables associated with depression, and to determine the role of depression in prediction of mortality. The prospective follow-up study of 128 patients (77 HD and 51 CAPD, 65 male, aged 53.8 +/- 13.5 years, dialysis duration 64.7 +/- 64.8 months) was carried out over 3 6 months. Depression by the Beck Depression Inventory-BDI-II score, laboratory parameters (hemoglobin, serum albumin and creatinine concentration), immunological status (cytokines and hsCRP), comorbidity by Index of Physical Impairment (IPI) and adequacy of dialysis by Kt/V were monitored. The overall prevalence of depression in the dialysis patients (BDI score >= 14) was 45.3%, and 28.2%, respectively, for moderate and severe depression (BDI >= 20). The most powerful variable associated with depression was IL-6, but associations with albumin, hemoglobin, creatinine and IPI score were also found. During the follow-up period 36 patients died, 7 patients left the cohort and 2 patients were transplanted. If IPI score was not included in the multivariate Cox analysis, the BDI score remained one of the best predictors of mortality along with albumin. In conclusion, because of the close association of depression with inflammation, malnutrition, and cardiovascular mortality, it could be speculated that depression is one branch of the MIA (malnutrition, inflammation, atherosclerosis) syndrome.
PB  - Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen
T2  - Clinical Nephrology
T1  - Could depression be a new branch of MIA syndrome?
VL  - 71
IS  - 2
SP  - 164
EP  - 172
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1251
ER  - 
@article{
author = "Simić-Ogrizović, Sanja and Jovanović, D. and Dopsaj, Violeta and Radović, M. and Šumarac, Zorica and Bogavac-Stanojević, Nataša and Stošović, Milan and Stanojević, M. and Nesić, V.",
year = "2009",
abstract = "The aims of the present study were to determine the prevalence of depression in our dialysis patients, to detect the most powerful variables associated with depression, and to determine the role of depression in prediction of mortality. The prospective follow-up study of 128 patients (77 HD and 51 CAPD, 65 male, aged 53.8 +/- 13.5 years, dialysis duration 64.7 +/- 64.8 months) was carried out over 3 6 months. Depression by the Beck Depression Inventory-BDI-II score, laboratory parameters (hemoglobin, serum albumin and creatinine concentration), immunological status (cytokines and hsCRP), comorbidity by Index of Physical Impairment (IPI) and adequacy of dialysis by Kt/V were monitored. The overall prevalence of depression in the dialysis patients (BDI score >= 14) was 45.3%, and 28.2%, respectively, for moderate and severe depression (BDI >= 20). The most powerful variable associated with depression was IL-6, but associations with albumin, hemoglobin, creatinine and IPI score were also found. During the follow-up period 36 patients died, 7 patients left the cohort and 2 patients were transplanted. If IPI score was not included in the multivariate Cox analysis, the BDI score remained one of the best predictors of mortality along with albumin. In conclusion, because of the close association of depression with inflammation, malnutrition, and cardiovascular mortality, it could be speculated that depression is one branch of the MIA (malnutrition, inflammation, atherosclerosis) syndrome.",
publisher = "Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen",
journal = "Clinical Nephrology",
title = "Could depression be a new branch of MIA syndrome?",
volume = "71",
number = "2",
pages = "164-172",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1251"
}
Simić-Ogrizović, S., Jovanović, D., Dopsaj, V., Radović, M., Šumarac, Z., Bogavac-Stanojević, N., Stošović, M., Stanojević, M.,& Nesić, V.. (2009). Could depression be a new branch of MIA syndrome?. in Clinical Nephrology
Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen., 71(2), 164-172.
https://hdl.handle.net/21.15107/rcub_farfar_1251
Simić-Ogrizović S, Jovanović D, Dopsaj V, Radović M, Šumarac Z, Bogavac-Stanojević N, Stošović M, Stanojević M, Nesić V. Could depression be a new branch of MIA syndrome?. in Clinical Nephrology. 2009;71(2):164-172.
https://hdl.handle.net/21.15107/rcub_farfar_1251 .
Simić-Ogrizović, Sanja, Jovanović, D., Dopsaj, Violeta, Radović, M., Šumarac, Zorica, Bogavac-Stanojević, Nataša, Stošović, Milan, Stanojević, M., Nesić, V., "Could depression be a new branch of MIA syndrome?" in Clinical Nephrology, 71, no. 2 (2009):164-172,
https://hdl.handle.net/21.15107/rcub_farfar_1251 .
43
50

Biochemical changes in menopause

Dopsaj, Violeta; Šumarac, Zorica

(Savez farmaceutskih udruženja Srbije, Beograd, 2005)

TY  - JOUR
AU  - Dopsaj, Violeta
AU  - Šumarac, Zorica
PY  - 2005
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/611
AB  - Physiological changes in menopause are the reflection of changes of circulating steroid hormone concentrations. The changes of menstrual cycles occurring just before menopause may be recorded best by higher FHS, normal LH concentrations and slightly increased estradiol level. Cessation of menstruation usually occurs when FSH concentration exceeds 40 IU/L in two separate measurements. In menopause, an altered hormonal status results in metabolic changes of various tissues and organs. Menopause in women carries higher risk of cardiovascular diseases, osteoporosis, thromboembolic disorders, impairments of cognitive functions and autoimmune diseases, etc. Termination of ovarian synthesis of estrogen, on one hand, and increased production of proinflammatory cytokines (TNF, IL-1, IL-6), on the other, provide conditions for inflammatory response which underlies many pathological processes. During and after menopause, lipid status is changed in women, as follows: higher concentrations of cholesterol, triglycerides, apo-B and LDL cholesterol and reduced HDL cholesterol. Bone density becomes lower with aging and depends upon duration of estrogen deficit in women after menopause, what increases the risk of osteoporosis. Menopause is also characterized by prothrombotic effects manifested by higher activity of FVII, FVIII and fibrinogen. The changes of hormone production of hypothalamus-hypophysis-ovarium axis in menopause, and responses of different non-productive somatic and nervous tissue to these respective have been the issue of many investigations.
AB  - Fiziološke promene u menopauzi odraz su promena u cirkulišućim koncentracijama steroidnih hormona. Promene u menstrualnom ciklusu koje nastaju neposredno pre menopauze najbolje se mogu registrovati kroz povišene koncentracije FSH, normalne vrednosti LH i blago povišeni estradiol. Potpuni gubitak menstrualnog ciklusa obično se dešava kada koncentracija FSH premaši 40 IU/L u dva pojedinačna određivanja. U menopauzi se kao posledica izmenjenog hormonskog statusa dešavaju metaboličke promene u različitim tkivima i organima. Menopauza donosi ženi veći rizik za nastanak kardiovaskularne bolesti, osteoporoze, tromboembolijskih poremećaja, poremećaja kognitivnih funkcija, autoimunih bolesti i dr. Prestanak ovarijalne sinteze estrogena s jedne, a povećana produkcija proinflamatornih citokina (TNF, IL-1, IL-6) sa druge strane stvaraju uslove za razvoj inflamatornog odgovora koji se nalazi u osnovi mnogih patoloških procesa. U menopauzi i posle menopauze žene imaju izmenjen lipidni status: povećane koncentracije holesterola, triglicerida, apo-B i LDL holesterola i smanjen HDL-holesterol. Koštana gustina se smanjuje sa starošću i zavisi od trajanja estrogenskog deficita kod žena posle menopauze što povećava rizik od nastanka osteoporoze. Menopauzu takođe karakterišu protrombotički efekti koji se manifestuju porastom aktivnosti FVII, FVIII i fibrinogena. Promene u produkciji hormona duž hipotalamus-hipofiza-ovarijum ose u menopauzi, i odgovori različitih nereproduktivnih somatskih tkiva i nervnog tkiva na te promene predmet su velikog broja istraživanja.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Biochemical changes in menopause
T1  - Promene biokemijskih parametara u menopauzi
VL  - 55
IS  - 2
SP  - 76
EP  - 90
UR  - https://hdl.handle.net/21.15107/rcub_farfar_611
ER  - 
@article{
author = "Dopsaj, Violeta and Šumarac, Zorica",
year = "2005",
abstract = "Physiological changes in menopause are the reflection of changes of circulating steroid hormone concentrations. The changes of menstrual cycles occurring just before menopause may be recorded best by higher FHS, normal LH concentrations and slightly increased estradiol level. Cessation of menstruation usually occurs when FSH concentration exceeds 40 IU/L in two separate measurements. In menopause, an altered hormonal status results in metabolic changes of various tissues and organs. Menopause in women carries higher risk of cardiovascular diseases, osteoporosis, thromboembolic disorders, impairments of cognitive functions and autoimmune diseases, etc. Termination of ovarian synthesis of estrogen, on one hand, and increased production of proinflammatory cytokines (TNF, IL-1, IL-6), on the other, provide conditions for inflammatory response which underlies many pathological processes. During and after menopause, lipid status is changed in women, as follows: higher concentrations of cholesterol, triglycerides, apo-B and LDL cholesterol and reduced HDL cholesterol. Bone density becomes lower with aging and depends upon duration of estrogen deficit in women after menopause, what increases the risk of osteoporosis. Menopause is also characterized by prothrombotic effects manifested by higher activity of FVII, FVIII and fibrinogen. The changes of hormone production of hypothalamus-hypophysis-ovarium axis in menopause, and responses of different non-productive somatic and nervous tissue to these respective have been the issue of many investigations., Fiziološke promene u menopauzi odraz su promena u cirkulišućim koncentracijama steroidnih hormona. Promene u menstrualnom ciklusu koje nastaju neposredno pre menopauze najbolje se mogu registrovati kroz povišene koncentracije FSH, normalne vrednosti LH i blago povišeni estradiol. Potpuni gubitak menstrualnog ciklusa obično se dešava kada koncentracija FSH premaši 40 IU/L u dva pojedinačna određivanja. U menopauzi se kao posledica izmenjenog hormonskog statusa dešavaju metaboličke promene u različitim tkivima i organima. Menopauza donosi ženi veći rizik za nastanak kardiovaskularne bolesti, osteoporoze, tromboembolijskih poremećaja, poremećaja kognitivnih funkcija, autoimunih bolesti i dr. Prestanak ovarijalne sinteze estrogena s jedne, a povećana produkcija proinflamatornih citokina (TNF, IL-1, IL-6) sa druge strane stvaraju uslove za razvoj inflamatornog odgovora koji se nalazi u osnovi mnogih patoloških procesa. U menopauzi i posle menopauze žene imaju izmenjen lipidni status: povećane koncentracije holesterola, triglicerida, apo-B i LDL holesterola i smanjen HDL-holesterol. Koštana gustina se smanjuje sa starošću i zavisi od trajanja estrogenskog deficita kod žena posle menopauze što povećava rizik od nastanka osteoporoze. Menopauzu takođe karakterišu protrombotički efekti koji se manifestuju porastom aktivnosti FVII, FVIII i fibrinogena. Promene u produkciji hormona duž hipotalamus-hipofiza-ovarijum ose u menopauzi, i odgovori različitih nereproduktivnih somatskih tkiva i nervnog tkiva na te promene predmet su velikog broja istraživanja.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Biochemical changes in menopause, Promene biokemijskih parametara u menopauzi",
volume = "55",
number = "2",
pages = "76-90",
url = "https://hdl.handle.net/21.15107/rcub_farfar_611"
}
Dopsaj, V.,& Šumarac, Z.. (2005). Biochemical changes in menopause. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 55(2), 76-90.
https://hdl.handle.net/21.15107/rcub_farfar_611
Dopsaj V, Šumarac Z. Biochemical changes in menopause. in Arhiv za farmaciju. 2005;55(2):76-90.
https://hdl.handle.net/21.15107/rcub_farfar_611 .
Dopsaj, Violeta, Šumarac, Zorica, "Biochemical changes in menopause" in Arhiv za farmaciju, 55, no. 2 (2005):76-90,
https://hdl.handle.net/21.15107/rcub_farfar_611 .

Laboratory diagnostics of chronic liver diseases

Šumarac, Zorica; Dopsaj, Violeta

(Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd, 2005)

TY  - JOUR
AU  - Šumarac, Zorica
AU  - Dopsaj, Violeta
PY  - 2005
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/645
AB  - Chronic liver diseases are conditions that are clinically manifested by duration longer than six months. According to etiological factors, they are classified as follows: infectious (chronic viral hepatitis), toxic (alcoholic hepatitis, drug- and toxin-associated), hereditary metabolic diseases, autoimmune and neoplastic diseases. Pathological changes include: hepatitis, cirrhosis and cholestasis. Diagnosis of these diseases is based on clinical picture, results of medical-biochemical and serological analyses, liver biopsy and other diagnostic methods, such as: ultrasonography, computerized tomography, esophagoduodenoscopy and endoscopic retrograde cholangiopancreatography. Chronic hepatitis is a clinical syndrome of heterogenous etiology, i.e., a group of diseases with necroinflammatory process in the liver, often followed by fibrosis and duration of more than six months. The impairment may progress to cirrhosis and hepatocellular cancer. Etiologically, chronic hepatitis is classified into several groups, such as: viral (hepatitis B and hepatitis C), autoimmune hepatitis (types 1, 2 and 3), autoimmune cholestatic diseases (primary biliary cirrhosis-PBC, and primary sclerosing cholangitis-PSC), drug-associated hepatitis, Wilson's disease, α 1 -antitripsine deficit, primary idiopathic hemochromatosis, cryptogenic hepatitis and non-alcoholic steatohepatitis. For differential diagnosis of these diseases, it is essential that initial evaluation includes the complete history of drug usage, alcohol consumption and ALT, AST, HBsAG and anti-HCV measurements. In persons with increased catalytic ALT activity and negative HBsAg and anti-HCV, it is necessary to determine the auto antibodies, Fe, TIBC and UIBC, ceruloplasmin, and α 1 -antitripsine phenotype. The diagnosis of chronic viral hepatitis requires determination of catalytic activity of ALT and specific serological tests: HBsAG, anti-HBs, HBeAg, anti-HBe, HBV-DNA, anti-HCV and HCV-RNA. Alcoholic liver disease is developed in several phases: from normal liver, through steatosis, alcoholic hepatitis to cirrhosis. In patients with verified history of alcohol consumption, it is necessary to determine the catalytic activity of γ-GT, AST, ALT, MCV and CDT. Determination of CDT and γ-GT is needed for monitoring of therapeutical effects, while liver biopsy is required for definite diagnosis. Cirrhosis is the end-stage of chronic liver diseases, and the most frequent causes are: acute and viral hepatitis, long-term and excessive alcohol consumption, metabolic and biliary diseases, autoimmune hepatitis, effects of drugs, chemical agents, etc. Chronic hepatitis developing to cirrhosis is characterized by two basic processes: necroinflammatory impairment and fibrosis. Necrotic inflammation is characterized by higher De Ritis coefficient with considerably higher activity of γ-GT and LDH. Reduced synthetic function is indicated by: lower ChE activity, decreased albumin concentration with predominant serum gamma-globulin and high IgG and IgA concentrations, lower concentrations of haptoglobin and transferrin as well as longer prothrombin time. Although liver biopsy is considered the method of choice for diagnosis of hepatic cirrhosis, determination of PGA index or Fibro test-Acti test (α 2 - macroglobulin, haptoglobin, γ-GT, total bilirubin, Apo-A I and ALT) is recommended as the alternative to biopsy, which exhibits the highest sensitivity, specificity as well as best predictive value for diagnosis of cirrhosis. HCC is the most common form of malignant liver tumors and may be the result of hepatic cirrhosis due to effects of hepatitis B and C, some toxins, α 1 AT deficit or hemochromatosis. Diagnosis is based on clinical picture, US, CT and MR imaging, liver biopsy and values of tumor markers, primarily: α-fetoprotein, carcinoembryonic antibody, and des-γ-carboxy prothrombin. The changes of biochemical parameters are not specific for tumor, but may serve to substantiate the diagnosis. In patients who are not alcohol consumers, chronic disease similar to alcoholic hepatitis, followed by steatosis, parenchymal inflammation and different forms of fibrosis is defined as non-alcoholic steatohepatitis (NASH). Liver biopsy is crucial for verification of NASH diagnosis. Metabolic liver diseases include: familial hyperbilirubinemia, primary hereditary hemochromatosis, Wilson's diseases, alpha-1-antitripsin deficiency, Reye's syndrome, etc. Diagnostic guidelines for differential diagnosis of familial hyperbilirubinemia are based on measurement of total and direct bilirubin concentrations. Primary hereditary hemochromatosis is an autosomal, recessive disorder where the iron is absorbed in larger quantities and deposited in parenchymal organs. The initial evaluation of hemochromatosis is grounded on verified higher saturation of transferrin (>45%) and unsaturated capacity of iron binding (<28 μmol/L). Genetic analysis is needed for definite diagnosis. Wilson's disease is hereditary disorder of copper metabolism characterized by deposition of toxic copper concentrations in tissues and organs. The most common diagnostic finding is low level of blood ceruloplasmin (< 0.17 g/L), higher concentration of free serum copper (>7 μmol/L), lower concentration of total copper, increased copper excretion via urine (up to 20 μmol/24h) and higher concentration of copper in liver tissue. α 1 AT deficit is an autosomal, recessive disorder with significantly lower α 1 -antitripsin values, giving rise to pulmonary emphysema, chronic liver diseases, cirrhosis and hepatocellular cancer. For making a diagnosis, it is necessary to measure serum α 1 AT concentration, phenotyping and genotyping. Reye's syndrome is a disease defined as acute, non-inflammatory encephalopathy associated with fat degeneration of the liver, with unknown etiology, and followed by general mitochondrial dysfunction. Differential diagnosis is necessary to rule out congenital metabolic defects, and determination of aminotransferases, glucose, PT, ammonia and free fat acids along with liver biopsy are crucial for verification of diagnosis. Autoimmune hepatic diseases include: autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Differential diagnosis involves the following measurements: anti-nuclear At, smooth muscle At, At to hepatic-renal-microsomal Ag, At to soluble-hepatic Ag, anti-mitochondrial At and perinuclear anti-neutrophil-cytoplasmic At, as well as utilization of endoscopic retrograde cholangiopancreatography.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Laboratory diagnostics of chronic liver diseases
T1  - Laboratorijska dijagnostika hroničnih oštećenja jetre
VL  - 24
IS  - SUPPL. 4
SP  - 61
EP  - 76
UR  - https://hdl.handle.net/21.15107/rcub_farfar_645
ER  - 
@article{
author = "Šumarac, Zorica and Dopsaj, Violeta",
year = "2005",
abstract = "Chronic liver diseases are conditions that are clinically manifested by duration longer than six months. According to etiological factors, they are classified as follows: infectious (chronic viral hepatitis), toxic (alcoholic hepatitis, drug- and toxin-associated), hereditary metabolic diseases, autoimmune and neoplastic diseases. Pathological changes include: hepatitis, cirrhosis and cholestasis. Diagnosis of these diseases is based on clinical picture, results of medical-biochemical and serological analyses, liver biopsy and other diagnostic methods, such as: ultrasonography, computerized tomography, esophagoduodenoscopy and endoscopic retrograde cholangiopancreatography. Chronic hepatitis is a clinical syndrome of heterogenous etiology, i.e., a group of diseases with necroinflammatory process in the liver, often followed by fibrosis and duration of more than six months. The impairment may progress to cirrhosis and hepatocellular cancer. Etiologically, chronic hepatitis is classified into several groups, such as: viral (hepatitis B and hepatitis C), autoimmune hepatitis (types 1, 2 and 3), autoimmune cholestatic diseases (primary biliary cirrhosis-PBC, and primary sclerosing cholangitis-PSC), drug-associated hepatitis, Wilson's disease, α 1 -antitripsine deficit, primary idiopathic hemochromatosis, cryptogenic hepatitis and non-alcoholic steatohepatitis. For differential diagnosis of these diseases, it is essential that initial evaluation includes the complete history of drug usage, alcohol consumption and ALT, AST, HBsAG and anti-HCV measurements. In persons with increased catalytic ALT activity and negative HBsAg and anti-HCV, it is necessary to determine the auto antibodies, Fe, TIBC and UIBC, ceruloplasmin, and α 1 -antitripsine phenotype. The diagnosis of chronic viral hepatitis requires determination of catalytic activity of ALT and specific serological tests: HBsAG, anti-HBs, HBeAg, anti-HBe, HBV-DNA, anti-HCV and HCV-RNA. Alcoholic liver disease is developed in several phases: from normal liver, through steatosis, alcoholic hepatitis to cirrhosis. In patients with verified history of alcohol consumption, it is necessary to determine the catalytic activity of γ-GT, AST, ALT, MCV and CDT. Determination of CDT and γ-GT is needed for monitoring of therapeutical effects, while liver biopsy is required for definite diagnosis. Cirrhosis is the end-stage of chronic liver diseases, and the most frequent causes are: acute and viral hepatitis, long-term and excessive alcohol consumption, metabolic and biliary diseases, autoimmune hepatitis, effects of drugs, chemical agents, etc. Chronic hepatitis developing to cirrhosis is characterized by two basic processes: necroinflammatory impairment and fibrosis. Necrotic inflammation is characterized by higher De Ritis coefficient with considerably higher activity of γ-GT and LDH. Reduced synthetic function is indicated by: lower ChE activity, decreased albumin concentration with predominant serum gamma-globulin and high IgG and IgA concentrations, lower concentrations of haptoglobin and transferrin as well as longer prothrombin time. Although liver biopsy is considered the method of choice for diagnosis of hepatic cirrhosis, determination of PGA index or Fibro test-Acti test (α 2 - macroglobulin, haptoglobin, γ-GT, total bilirubin, Apo-A I and ALT) is recommended as the alternative to biopsy, which exhibits the highest sensitivity, specificity as well as best predictive value for diagnosis of cirrhosis. HCC is the most common form of malignant liver tumors and may be the result of hepatic cirrhosis due to effects of hepatitis B and C, some toxins, α 1 AT deficit or hemochromatosis. Diagnosis is based on clinical picture, US, CT and MR imaging, liver biopsy and values of tumor markers, primarily: α-fetoprotein, carcinoembryonic antibody, and des-γ-carboxy prothrombin. The changes of biochemical parameters are not specific for tumor, but may serve to substantiate the diagnosis. In patients who are not alcohol consumers, chronic disease similar to alcoholic hepatitis, followed by steatosis, parenchymal inflammation and different forms of fibrosis is defined as non-alcoholic steatohepatitis (NASH). Liver biopsy is crucial for verification of NASH diagnosis. Metabolic liver diseases include: familial hyperbilirubinemia, primary hereditary hemochromatosis, Wilson's diseases, alpha-1-antitripsin deficiency, Reye's syndrome, etc. Diagnostic guidelines for differential diagnosis of familial hyperbilirubinemia are based on measurement of total and direct bilirubin concentrations. Primary hereditary hemochromatosis is an autosomal, recessive disorder where the iron is absorbed in larger quantities and deposited in parenchymal organs. The initial evaluation of hemochromatosis is grounded on verified higher saturation of transferrin (>45%) and unsaturated capacity of iron binding (<28 μmol/L). Genetic analysis is needed for definite diagnosis. Wilson's disease is hereditary disorder of copper metabolism characterized by deposition of toxic copper concentrations in tissues and organs. The most common diagnostic finding is low level of blood ceruloplasmin (< 0.17 g/L), higher concentration of free serum copper (>7 μmol/L), lower concentration of total copper, increased copper excretion via urine (up to 20 μmol/24h) and higher concentration of copper in liver tissue. α 1 AT deficit is an autosomal, recessive disorder with significantly lower α 1 -antitripsin values, giving rise to pulmonary emphysema, chronic liver diseases, cirrhosis and hepatocellular cancer. For making a diagnosis, it is necessary to measure serum α 1 AT concentration, phenotyping and genotyping. Reye's syndrome is a disease defined as acute, non-inflammatory encephalopathy associated with fat degeneration of the liver, with unknown etiology, and followed by general mitochondrial dysfunction. Differential diagnosis is necessary to rule out congenital metabolic defects, and determination of aminotransferases, glucose, PT, ammonia and free fat acids along with liver biopsy are crucial for verification of diagnosis. Autoimmune hepatic diseases include: autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Differential diagnosis involves the following measurements: anti-nuclear At, smooth muscle At, At to hepatic-renal-microsomal Ag, At to soluble-hepatic Ag, anti-mitochondrial At and perinuclear anti-neutrophil-cytoplasmic At, as well as utilization of endoscopic retrograde cholangiopancreatography.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Laboratory diagnostics of chronic liver diseases, Laboratorijska dijagnostika hroničnih oštećenja jetre",
volume = "24",
number = "SUPPL. 4",
pages = "61-76",
url = "https://hdl.handle.net/21.15107/rcub_farfar_645"
}
Šumarac, Z.,& Dopsaj, V.. (2005). Laboratory diagnostics of chronic liver diseases. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 24(SUPPL. 4), 61-76.
https://hdl.handle.net/21.15107/rcub_farfar_645
Šumarac Z, Dopsaj V. Laboratory diagnostics of chronic liver diseases. in Jugoslovenska medicinska biohemija. 2005;24(SUPPL. 4):61-76.
https://hdl.handle.net/21.15107/rcub_farfar_645 .
Šumarac, Zorica, Dopsaj, Violeta, "Laboratory diagnostics of chronic liver diseases" in Jugoslovenska medicinska biohemija, 24, no. SUPPL. 4 (2005):61-76,
https://hdl.handle.net/21.15107/rcub_farfar_645 .